Goldman Sachs Group Inc Trevena Inc Transaction History

Goldman Sachs Group Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 May 14, 2024	BUY	$0.2 - $0.5 $23,805 - $59,513	119,026 New	119,026 $49,000
Q2 2022 Aug 15, 2022	SELL	$0.2 - $0.5 $3,304 - $8,260	-16,520 Reduced 12.19%	119,026 $49,000
Q1 2022 May 16, 2022	SELL	$0.41 - $0.63 $132,382 - $203,416	-322,883 Reduced 70.43%	135,546 $75,000
Q4 2021 Feb 14, 2022	BUY	$0.57 - $1.29 $163,805 - $370,717	287,378 Added 168.01%	458,429 $267,000
Q3 2021 Nov 10, 2021	BUY	$1.11 - $1.7 $189,866 - $290,786	171,051 New	171,051 $210,000

Ticker TRVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 173,680,992
Market Cap $273M
Description
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.